Irritable Bowel Syndrome - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 146 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Irritable Bowel Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Irritable Bowel Syndrome - Pipeline Review, H2 2014', provides an overview of the Irritable Bowel Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome Overview 10
Therapeutics Development 11
Pipeline Products for Irritable Bowel Syndrome - Overview 11
Pipeline Products for Irritable Bowel Syndrome - Comparative Analysis 12
Irritable Bowel Syndrome - Therapeutics under Development by Companies 13
Irritable Bowel Syndrome - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Irritable Bowel Syndrome - Products under Development by Companies 19
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 20
AstraZeneca PLC 20
Sumitomo Dainippon Pharma Co., Ltd. 21
Takeda Pharmaceutical Company Limited 22
Astellas Pharma Inc. 23
Ono Pharmaceutical Co., Ltd. 24
SK Chemicals Co., Ltd. 25
Teva Pharmaceutical Industries Limited 26
A. Menarini Industrie Farmaceutiche Riunite Srl 27
AlbireoPharma 28
Lexicon Pharmaceuticals, Inc. 29
Yuhan Corporation 30
Alba Therapeutics Corporation 31
Ironwood Pharmaceuticals, Inc. 32
Rottapharm SpA 33
Tioga Pharmaceuticals, Inc. 34
Synthetic Biologics, Inc. 35
Drais Pharmaceuticals, Inc. 36
Synergy Pharmaceuticals, Inc. 37
Protagonist Therapeutics Inc. 38
Alfa Wassermann S.p.A 39
RaQualia Pharma Inc. 40
Furiex Pharmaceuticals, Inc. 41
Hanmi Pharmaceuticals, Co. Ltd. 42
X-BODY BioSciences, Inc. 43
ImmusanT, Inc. 44
AltheRx Pharmaceuticals, Inc. 45
GIcare Pharma Inc 46
Dong-A Socio Group 47
Irritable Bowel Syndrome - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 53
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
rifaximin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
eluxadoline - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ibodutant - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
linaclotide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
asimadoline - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
dexloxiglumide - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
rifaximin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
tenapanor hydrochloride - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
plecanatide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
solabegron hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
elobixibat - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ONO-2952 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
LX-1033 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ASP-7147 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
(Bacillus subtilis + mosapride + Streptococcus faecium) - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
DSP-6952 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
SKI-3246 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SYN-010 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
larazotide acetate - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
DA-6886 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
YH-12852 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
MDT-006 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
RQ-00202730 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
RQ-00310941 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
GIC-1001 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ASP-1017 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
TAK-480 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Nexvax-2 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Synthetic Peptides for Gastrointestinal Disorders - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Monoclonal Antibody to Inhibit M3 for Irritable Bowel Syndrome - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
SYN-007 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Peptides for Irritable Bowel Syndrome and Inflammatory Bowel Disease - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Irritable Bowel Syndrome - Recent Pipeline Updates 108
Irritable Bowel Syndrome - Dormant Projects 132
Irritable Bowel Syndrome - Discontinued Products 133
Irritable Bowel Syndrome - Product Development Milestones 134
Featured News & Press Releases 134
Sep 18, 2014: Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea 134
Sep 02, 2014: 4D pharma Provides Update On Blautix for the treatment of Irritable Bowel Syndrome 134
Sep 02, 2014: Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 135
Sep 02, 2014: Salix Submits Response to XIFAXAN 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea 136
Aug 11, 2014: Salix Announces Important Topline Results for Microbiome, Culture & Susceptibility, and Key Secondary Efficacy Results for TARGET 3, Rifaximin IBS-D Repeat Treatment Study 137
Jul 08, 2014: Synergy Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Plecanatide in Irritable Bowel Syndrome with Constipation 138
May 01, 2014: Synergy Pharmaceuticals Announces Positive Results of Plecanatide Phase 2b Study in Patients with Irritable Bowel Syndrome with Constipation 139
Apr 10, 2014: Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS 140
Feb 10, 2014: Ironwood Receives Notice of Allowance for Methods of Use Formulation Patent Expected to Extend LINZESS Patent Protection Through 2031 141
Feb 04, 2014: Furiex Pharmaceuticals Announces Positive Top-Line Results of Two Pivotal Phase III Clinical Trials of Eluxadoline in Patients with IBS-d 142
Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 146
Disclaimer 146

List of Tables
Number of Products under Development for Irritable Bowel Syndrome, H2 2014 11
Number of Products under Development for Irritable Bowel Syndrome - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Irritable Bowel Syndrome - Pipeline by AstraZeneca PLC., H2 2014 20
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 21
Irritable Bowel Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 22
Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H2 2014 23
Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 24
Irritable Bowel Syndrome - Pipeline by SK Chemicals Co., Ltd., H2 2014 25
Irritable Bowel Syndrome - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 26
Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 27
Irritable Bowel Syndrome - Pipeline by AlbireoPharma, H2 2014 28
Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014 29
Irritable Bowel Syndrome - Pipeline by Yuhan Corporation, H2 2014 30
Irritable Bowel Syndrome - Pipeline by Alba Therapeutics Corporation, H2 2014 31
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2014 32
Irritable Bowel Syndrome - Pipeline by Rottapharm SpA, H2 2014 33
Irritable Bowel Syndrome - Pipeline by Tioga Pharmaceuticals, Inc., H2 2014 34
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H2 2014 35
Irritable Bowel Syndrome - Pipeline by Drais Pharmaceuticals, Inc., H2 2014 36
Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H2 2014 37
Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc., H2 2014 38
Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H2 2014 39
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H2 2014 40
Irritable Bowel Syndrome - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014 41
Irritable Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 42
Irritable Bowel Syndrome - Pipeline by X-BODY BioSciences, Inc., H2 2014 43
Irritable Bowel Syndrome - Pipeline by ImmusanT, Inc., H2 2014 44
Irritable Bowel Syndrome - Pipeline by AltheRx Pharmaceuticals, Inc., H2 2014 45
Irritable Bowel Syndrome - Pipeline by GIcare Pharma Inc, H2 2014 46
Irritable Bowel Syndrome - Pipeline by Dong-A Socio Group, H2 2014 47
Assessment by Monotherapy Products, H2 2014 48
Assessment by Combination Products, H2 2014 49
Number of Products by Stage and Target, H2 2014 52
Number of Products by Stage and Mechanism of Action, H2 2014 55
Number of Products by Stage and Route of Administration, H2 2014 58
Number of Products by Stage and Molecule Type, H2 2014 60
Irritable Bowel Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 108
Irritable Bowel Syndrome - Dormant Projects, H2 2014 132
Irritable Bowel Syndrome - Discontinued Products, H2 2014 133